Literature DB >> 18363034

Central dopamine deficiency in pure autonomic failure.

David S Goldstein1, Courtney Holmes, Takuya Sato, Miya Bernson, Neptune Mizrahi, Richard Imrich, Gilberto Carmona, Yehonatan Sharabi, Alexander O Vortmeyer.   

Abstract

OBJECTIVE: Pure autonomic failure (PAF) and Parkinson's disease (PD) share several clinical laboratory abnormalities; however, PAF is not associated with parkinsonism. In this study, we tested the hypothesis that preservation of nigrostriatal dopaminergic innervation explains the absence of motor dysfunction in PAF. M
METHODS: Patients with PAF (N = 5) or PD (N = 21) and control subjects (N= 14) had brain 6-[18F]fluorodopa positron emission tomographic scanning and cerebrospinal fluid catechol measurements. A patient with PAF and another with PD had rapid postmortem striatal, nigral, and sympathetic ganglion sampling, with assays of catechols and tyrosine hydroxylase activity.
RESULTS: The PAF and PD groups had similarly low mean substantia nigra (SN):occipital (OCC) ratios of 6-[18F]fluorodopa-derived radioactivity and similarly low cerebrospinal fluid dihydroxyphenylacetic acid and DOPA levels. Only the PD group, however, had low PUT:OCC, caudate:OCC, or PUT:SN ratios. The PAF and PD cases had similarly low SN tissue concentrations of dopamine and tyrosine hydroxylase activity, but the PD patient had tenfold lower PUT dopamine and the PAF patient 15-fold lower myocardial norepinephrine concentrations.
CONCLUSIONS: Surprisingly, PAF and PD entail similarly severe nigral and overall central dopaminergic denervation. There is more severe loss of striatal dopaminergic terminals in PD than in PAF and more severe loss of sympathetic noradrenergic terminals in PAF than in PD. These differences explain the distinctive clinical manifestations of the two Lewy body diseases. Parkinsonism appears to reflect striatal dopamine deficiency rather than loss of nigral dopaminergic neurons per se.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363034     DOI: 10.1007/s10286-008-0457-0

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  33 in total

1.  Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy.

Authors:  S Orimo; T Oka; H Miura; K Tsuchiya; F Mori; K Wakabayashi; T Nagao; M Yokochi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease.

Authors:  Satoshi Orimo; Takeshi Amino; Yoshinori Itoh; Atsushi Takahashi; Tohru Kojo; Toshiki Uchihara; Kuniaki Tsuchiya; Fumiaki Mori; Koichi Wakabayashi; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2005-06-03       Impact factor: 17.088

Review 3.  Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy.

Authors:  H Kaufmann
Journal:  Clin Auton Res       Date:  1996-04       Impact factor: 4.435

4.  Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment.

Authors:  David S Goldstein; Basil A Eldadah; Courtney Holmes; Sandra Pechnik; Jeffrey Moak; Ahmed Saleem; Yehonatan Sharabi
Journal:  Hypertension       Date:  2005-10-10       Impact factor: 10.190

5.  Noninvasive detection of sympathetic neurocirculatory failure.

Authors:  D S Goldstein; C Tack
Journal:  Clin Auton Res       Date:  2000-10       Impact factor: 4.435

6.  Cardiac sympathetic denervation in Parkinson disease.

Authors:  D S Goldstein; C Holmes; S T Li; S Bruce; L V Metman; R O Cannon
Journal:  Ann Intern Med       Date:  2000-09-05       Impact factor: 25.391

Review 7.  Neuropathology of autonomic nervous system in Parkinson's disease.

Authors:  K Wakabayashi; H Takahashi
Journal:  Eur Neurol       Date:  1997       Impact factor: 1.710

8.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection.

Authors:  C Holmes; G Eisenhofer; D S Goldstein
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-04

Review 9.  Dysautonomia in Parkinson's disease: neurocardiological abnormalities.

Authors:  David S Goldstein
Journal:  Lancet Neurol       Date:  2003-11       Impact factor: 44.182

10.  Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension.

Authors:  David S Goldstein; Courtney Holmes; Nicholas Patronas; Irwin J Kopin
Journal:  Clin Sci (Lond)       Date:  2003-06       Impact factor: 6.124

View more
  16 in total

1.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

2.  A cross-sectional study contrasting olfactory function in autonomic disorders.

Authors:  E M Garland; S R Raj; A C Peltier; D Robertson; I Biaggioni
Journal:  Neurology       Date:  2011-02-01       Impact factor: 9.910

3.  Cardiac sympathetic neuroimaging: summary of the First International Symposium.

Authors:  David S Goldstein; Satoshi Orimo
Journal:  Clin Auton Res       Date:  2009-03-06       Impact factor: 4.435

4.  Patients as a scientific resource: comments on receiving the Ahrens award.

Authors:  David S Goldstein
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

5.  Natural history of pure autonomic failure: A United States prospective cohort.

Authors:  Horacio Kaufmann; Lucy Norcliffe-Kaufmann; Jose-Alberto Palma; Italo Biaggioni; Phillip A Low; Wolfgang Singer; David S Goldstein; Amanda C Peltier; Cyndia A Shibao; Christopher H Gibbons; Roy Freeman; David Robertson
Journal:  Ann Neurol       Date:  2017-02       Impact factor: 10.422

6.  Elevated cerebrospinal fluid ratios of cysteinyl-dopamine/3,4-dihydroxyphenylacetic acid in parkinsonian synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Patricia Sullivan; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2016-07-20       Impact factor: 4.891

7.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

8.  Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.

Authors:  Yehonatan Sharabi; Richard Imrich; Courtney Holmes; Sandra Pechnik; David S Goldstein
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

9.  Association of anosmia with autonomic failure in Parkinson disease.

Authors:  David S Goldstein; LaToya Sewell; Courtney Holmes
Journal:  Neurology       Date:  2010-01-19       Impact factor: 9.910

10.  Pioneer Award Address: ignorance isn't biased: comments on receiving the Pioneer Award.

Authors:  David S Goldstein
Journal:  Cleve Clin J Med       Date:  2009-04       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.